Precigen, Inc.
NASDAQ:PGENBiotechnology
-$0.10 today
- Market cap
- $1.53B
- Beta
- 1.06
- P/E (TTM)
- -7.1
- EPS (TTM)
- -$0.65
Volume 4.27M
Average 4.72M
PGEN Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Precigen, Inc.NASDAQ: PGEN
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development declines year over year
Q2 FY2026 research & development of $7.28M fell 36.6% year over year, behind the -30.0% change in trailing-twelve-month research & development. Sequentially, it rose 36.9% from the prior quarter. Over 3 fiscal years it compounded at -5.3% a year.
Context
- Research & development amounted to 413.7% of revenue in FY2025, down 938.4 pp from a year earlier.
- Research & development increased in 2 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -36.6% toward the trailing-twelve-month pace of -30.0%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
USD · from the income statement
- Latest · FY2025
- 40.06M USD
- Year-over-year change
- -24.5%
- 4-year CAGR
- -4.4%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 40.06M | -24.5% |
| FY2024 | 2024-12-31 | 53.07M | +9.2% |
| FY2023 | 2023-12-31 | 48.61M | +3.1% |
| FY2022 | 2022-12-31 | 47.17M | -1.6% |
| FY2021 | 2021-12-31 | 47.93M | — |
Research & Development vs competitors
How PGEN compares with its peers on the latest reported figures
- PGEN's LTM Jun 2026 research & development of $31.33M is the 7th highest of the 8 companies compared; the peer median is $137.53M.
- Its year-over-year change of -30.0% is the 7th highest of 8, against a peer median of -14.3%.
- Research & development amounts to 36.6% of revenue for PGEN, versus a peer median of 221.0%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $361.17M | -21.5% | -2.5% | 546.5% | |
| LTM Sep 2026 | $283.28M | +1.6% | -16.9% | 1125.4% | |
| LTM Mar 2026 | $228.65M | +12.8% | -2.0% | 260.4% | |
| LTM Mar 2026 | $137.53M | -14.3% | -5.0% | — | |
| LTM Mar 2026 | $66.19M | -62.3% | -19.9% | 171.1% | |
| LTM Mar 2026 | $53.36M | -10.8% | +5.5% | 118.4% | |
| LTM Jun 2026 | $31.33M | -30.0% | -5.3% | 36.6% | |
| LTM Mar 2026 | $26.43M | -28.8% | -2.5% | 181.7% | |
| Peer median (excluding PGEN) | $137.53M | -14.3% | -2.5% | 221.0% | |
Competitors are the stored peer set for PGEN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 14.27M | 26.91M | 6.23M | 3.93M | 9.68M |
| Cost of Revenue | 53.68M | 6.34M | 6.12M | 4.27M | 6.1M |
| Gross Profit | (39.41M) | 20.57M | 106K | (342K) | 3.59M |
| Gross Margin | -276.2% | 76.4% | 1.7% | -8.7% | 37.1% |
| Research & Development | 47.93M | 47.17M | 48.61M | 53.07M | 40.06M |
| Selling, General & Admin | 0 | 48.01M | 40.42M | 41.29M | 70.13M |
| Operating Expenses | 52.54M | 96.3M | 99.86M | 134.69M | 110.19M |
| Depreciation & Amortization | 13.76M | 10.77M | 6.67M | 4.53M | 3.2M |
| EBITDA | (77.64M) | (62.43M) | (89.23M) | (123.5M) | (243.57M) |
| EBITDA Margin | -544.2% | -232.0% | -1433.3% | -3146.4% | -2515.2% |
| Operating Income | (91.95M) | (75.73M) | (99.76M) | (135.03M) | (106.6M) |
| Operating Margin | -644.5% | -281.4% | -1602.5% | -3440.2% | -1100.8% |
| Interest Income | 171K | 133K | 3.24M | 1.42M | 3.22M |
| Interest Expense | 18.76M | 6.77M | 468K | 6K | 3.87M |
| Other Income / Expenses | (19.02M) | (4.24M) | 3.4M | 7M | (144.04M) |
| Income Before Tax | (110.97M) | (79.97M) | (96.36M) | (128.03M) | (250.64M) |
| Pre-Tax Margin | -777.8% | -297.2% | -1548.0% | -3261.9% | -2588.2% |
| Income Tax Expense | (160K) | (189K) | (458K) | (1.79M) | 3K |
| Net Income | (92.17M) | 28.32M | (95.9M) | (126.24M) | (250.64M) |
| Net Margin | -646.0% | 105.2% | -1540.6% | -3216.2% | -2588.2% |
| EPS (Basic) | (0.47) | (0.33) | (0.39) | (0.47) | (1.41) |
| EPS (Diluted) | (0.47) | (0.40) | (0.39) | (0.47) | (1.41) |
| Weighted Avg Shares | 197.76M | 200.36M | 244.54M | 267.73M | 304.71M |
| Weighted Avg Shares (Diluted) | 197.76M | 200.36M | 244.54M | 267.73M | 304.71M |
Precigen, Inc.
NASDAQ:PGEN
Intrinsic Alpha fair value
Locked
Current Price
$4.27
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.